TransDerm is dedicated to developing therapeutics for skin disorders. In partnership with the International Pachyonychia Congenita Consortium (IPCC) and the PC Project (www.pachyonychia.org), different avenues are veing investigated tha might help patients suffering from the very rare skin disorder, pachyonychia congenita (PC). The firm's interets also include the development of methodologies efficiently todeliver nucleic acid (including siRNAs) to inhibit target gene expression in skin. To that end, TransDerm is building on the powerful RNAi method of inhibiting gene expression using short interfering RNAs (siRNAs). These small double-stranded RNA molecules are designed so that one strand is complementary to the intended target. Principals are also workingo n patient-friendly siRNA delivery technologies. The firm's proprietary lipid-based formulation, genecreme -- containing siRNA against intended gene target -- is topically applied to the skin in a patient-friendly manner, similar to applying sunscreen (patent pending).
